Sparse Modeling Reveals miRNA Signatures for Diagnostics of Inflammatory Bowel Disease

PLoS One. 2015 Oct 14;10(10):e0140155. doi: 10.1371/journal.pone.0140155. eCollection 2015.

Abstract

The diagnosis of inflammatory bowel disease (IBD) still remains a clinical challenge and the most accurate diagnostic procedure is a combination of clinical tests including invasive endoscopy. In this study we evaluated whether systematic miRNA expression profiling, in conjunction with machine learning techniques, is suitable as a non-invasive test for the major IBD phenotypes (Crohn's disease (CD) and ulcerative colitis (UC)). Based on microarray technology, expression levels of 863 miRNAs were determined for whole blood samples from 40 CD and 36 UC patients and compared to data from 38 healthy controls (HC). To further discriminate between disease-specific and general inflammation we included miRNA expression data from other inflammatory diseases (inflammation controls (IC): 24 chronic obstructive pulmonary disease (COPD), 23 multiple sclerosis, 38 pancreatitis and 45 sarcoidosis cases) as well as 70 healthy controls from previous studies. Classification problems considering 2, 3 or 4 groups were solved using different types of penalized support vector machines (SVMs). The resulting models were assessed regarding sparsity and performance and a subset was selected for further investigation. Measured by the area under the ROC curve (AUC) the corresponding median holdout-validated accuracy was estimated as ranging from 0.75 to 1.00 (including IC) and 0.89 to 0.98 (excluding IC), respectively. In combination, the corresponding models provide tools for the distinction of CD and UC as well as CD, UC and HC with expected classification error rates of 3.1 and 3.3%, respectively. These results were obtained by incorporating not more than 16 distinct miRNAs. Validated target genes of these miRNAs have been previously described as being related to IBD. For others we observed significant enrichment for IBD susceptibility loci identified in earlier GWAS. These results suggest that the proposed miRNA signature is of relevance for the etiology of IBD. Its diagnostic value, however, should be further evaluated in large, independent, clinically well characterized cohorts.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Algorithms
  • Cluster Analysis
  • Computational Biology / methods
  • Female
  • Gene Expression Profiling
  • Gene Expression Regulation
  • Genetic Predisposition to Disease
  • Humans
  • Inflammatory Bowel Diseases / diagnosis*
  • Inflammatory Bowel Diseases / genetics*
  • Inflammatory Bowel Diseases / therapy
  • Male
  • MicroRNAs / genetics*
  • Middle Aged
  • Models, Statistical*
  • RNA Interference
  • RNA, Messenger / genetics
  • Reproducibility of Results
  • Support Vector Machine
  • Transcriptome*
  • Young Adult

Substances

  • MicroRNAs
  • RNA, Messenger

Grants and funding

This study was supported by the German Ministry of Education and Research (BMBF) program e:Med sysINFLAME (http://www.gesundheitsforschung-bmbf.de/de/5111.php, no.: 01ZX1306A) and received infrastructure support from the Deutsche Forschungsgemeinschaft (DFG) Cluster of Excellence ‘Inflammation at Interfaces’ (http://www.inflammation-at-interfaces.de, no.: XC306/2). Andre Franke receives an endowment professorship (Peter Hans Hofschneider Professorship) of the “Stiftung Experimentelle Biomedizin” located in Zuerich, Switzerland.